Renumathy Dhanasekaran

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1830250/publications.pdf

Version: 2024-02-01

129 papers	28,134 citations	41258 49 h-index	25716 108 g-index
137 all docs	137 docs citations	137 times ranked	38058 citing authors

#	Article	IF	Citations
1	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	6.6	3,706
2	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	13.5	2,277
3	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	13.5	2,111
4	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	13.5	1,794
5	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	13.5	1,718
6	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	13.5	1,670
7	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell, 2018, 173, 338-354.e15.	13.5	1,417
8	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	2.9	801
9	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	7.7	750
10	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	2.9	683
11	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	7.7	623
12	Pathogenic Germline Variants in 10,389 Adult Cancers. Cell, 2018, 173, 355-370.e14.	13.5	620
13	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	2.9	605
14	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
15	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	7.7	478
16	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Reports, 2018, 23, 227-238.e3.	2.9	407
17	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	7.7	400
18	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396

#	Article	IF	Citations
19	Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology, 2021, 74, 567-577.	1.8	377
20	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	2.9	333
21	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Reports, 2018, 25, 1304-1317.e5.	2.9	329
22	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	2.9	284
23	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	13.5	272
24	The MYC oncogene â€" the grand orchestrator of cancer growth and immune evasion. Nature Reviews Clinical Oncology, 2022, 19, 23-36.	12.5	253
25	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	2.9	245
26	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	13.5	228
27	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary resultsÂfrom an international registry. Journal of Hepatology, 2020, 73, 705-708.	1.8	213
28	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.	2.9	205
29	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	2.9	204
30	Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). Journal of Surgical Oncology, 2010, 101, 476-480.	0.8	196
31	Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. The Lancet Gastroenterology and Hepatology, 2020, 5, 1008-1016.	3.7	194
32	Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clinical Gastroenterology and Hepatology, 2021, 19, 1469-1479.e19.	2.4	179
33	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	2.9	177
34	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepatic Medicine: Evidence and Research, 2012, 4, 19.	0.9	170
35	Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Research, 2016, 5, 879.	0.8	159
36	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509.	0.6	145

#	Article	IF	Citations
37	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. Cell Systems, 2018, 7, 422-437.e7.	2.9	134
38	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology, 2019, 157, 1253-1263.e2.	0.6	131
39	Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax in Patients With Cirrhosis. American Journal of Gastroenterology, 2010, 105, 635-641.	0.2	125
40	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology, 2019, 156, 1683-1692.e1.	0.6	121
41	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	2.9	119
42	Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncology Reports, 2013, 29, 1259-1267.	1.2	108
43	Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. , 2018, 6, 125.		85
44	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	2.9	83
45	Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2013, 24, 307-315.	0.2	68
46	Vasodilatorâ€stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11â€dependent plasma membrane targeting of transforming growth factor beta receptors. Hepatology, 2015, 61, 361-374.	3.6	60
47	Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVIDâ€19): U.S. Multicenter Experience. Hepatology, 2020, 72, 1900-1911.	3.6	60
48	Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium. Gastroenterology, 2021, 161, 1502-1512.	0.6	57
49	Outcome of COVIDâ€19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology, 2021, 73, 2099-2109.	3.6	56
50	Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers. Hepatology, 2021, 73, 2342-2360.	3.6	53
51	Liver Test Results Do Not Identify Liver Disease in Adults With Î±1-Antitrypsin Deficiency. Clinical Gastroenterology and Hepatology, 2012, 10, 1278-1283.	2.4	50
52	Transcriptional Induction of Periostin by a Sulfatase 2â€“TGFÎ²1â€“SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. Cancer Research, 2017, 77, 632-645.	0.4	50
53	Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/Î²-catenin-induced FGF18 expression in hepatocellular carcinoma. Oncogene, 2018, 37, 1220-1236.	2.6	48
54	Activation of the transforming growth factorâ€Î²/SMAD transcriptional pathway underlies a novel tumorâ€promoting role of sulfatase 1 in hepatocellular carcinoma. Hepatology, 2015, 61, 1269-1283.	3.6	47

#	Article	IF	Citations
55	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications, 2020, 11, 2860.	5.8	45
56	YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget, 2018, 9, 5892-5905.	0.8	45
57	Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. Hpb, 2010, 12, 174-180.	0.1	43
58	Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 27-34.	0.6	43
59	Clinical implications of basic research in hepatocellular carcinoma. Journal of Hepatology, 2016, 64, 736-745.	1.8	42
60	One world, one pandemic, many guidelines: management of liver diseases during COVID-19. Gut, 2020, 69, 1369-1372.	6.1	39
61	MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. ELife, 2020, 9, .	2.8	38
62	A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma. Hepatology, 2019, 70, 1056-1058.	3.6	37
63	Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget, 2018, 9, 5517-5528.	0.8	33
64	Impact of fibrosis progression on clinical outcome in patients treated for postâ€transplant hepatitis C recurrence. Liver International, 2015, 35, 2433-2441.	1.9	27
65	Effects of immunosuppressive drugs on COVIDâ€19 severity in patients with autoimmune hepatitis. Liver International, 2022, 42, 607-614.	1.9	26
66	Management of Immunosuppression in Liver Transplantation. Clinics in Liver Disease, 2017, 21, 337-353.	1.0	25
67	Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatology Communications, 2021, 5, 1972-1986.	2.0	24
68	Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomographyâ€“Computed Tomography in Predicting Survival in Patients with Unresectable Metastatic Melanoma to the Liver Undergoing Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2012, 23, 943-948.	0.2	20
69	MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC. Molecular Therapy - Nucleic Acids, 2020, 21, 850-859.	2.3	17
70	Decline in Annual Mortality of Hepatitis C Virusâ€“Related Hepatocellular Carcinoma in the United States, From 2009 to 2018. Gastroenterology, 2020, 159, 1558-1560.e2.	0.6	17
71	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 1197-1204.	0.2	16
72	Chinese Skullcap in Move Free Arthritis Supplement Causes Drug Induced Liver Injury and Pulmonary Infiltrates. Case Reports in Hepatology, 2013, 2013, 1-4.	0.4	16

#	Article	IF	Citations
73	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2020, 18, 974-983.	2.4	16
74	Genomic Landscape of HCC. Current Hepatology Reports, 2020, 19, 448-461.	0.4	15
75	Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 345-350.	0.6	13
76	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 410-420.	0.9	13
77	Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)â€”Multi-Omic and Singulomic Approaches. Seminars in Liver Disease, 2021, 41, 009-018.	1.8	13
78	Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. Pathology Research and Practice, 2012, 208, 15-21.	1.0	11
79	Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities With Chronic Liver Diseases. Gastroenterology, 2021, 160, 1406-1409.e3.	0.6	11
80	Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin.. Journal of Clinical Oncology, 2010, 28, 4162-4162.	0.8	10
81	The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex. Journal of Biological Chemistry, 2020, 295, 2698-2712.	1.6	9
82	Roadmap to resuming care for liver diseases after coronavirus diseaseâ€2019. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 885-892.	1.4	9
83	Rare Case of Adult Undifferentiated (Embryonal) Sarcoma of the Liver Treated with Liver Transplantation: Excellent Long-Term Survival. Case Reports in Hepatology, 2012, 2012, 1-3.	0.4	7
84	Predictors of early mortality post transjugular intrahepatic portosystemic shunts and the role of hepatic venous pressure gradient. Gastrointestinal Intervention, 2012, 1, 63-68.	0.1	7
85	Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Current Gastroenterology Reports, 2015, 17, 34.	1.1	7
86	The Liver in Oncology. Clinics in Liver Disease, 2017, 21, 697-707.	1.0	7
87	Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation. Hepatology Communications, 2021, 5, 516-525.	2.0	7
88	Challenges of recurrent hepatitis C in the liver transplant patient. World Journal of Gastroenterology, 2014, 20, 3391.	1.4	7
89	Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). Current Treatment Options in Gastroenterology, 2021, 19, 351-368.	0.3	6
90	Morphological heterogeneity in beta-cateninâ€“mutated hepatocellular carcinomas: implications for tumor molecular classification. Human Pathology, 2022, 119, 15-27.	1.1	6

#	Article	IF	Citations
91	Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer. Hepatology, 2021, 73, 1611-1614.	3.6	5
92	MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies. Blood, 2018, 132, 2619-2619.	0.6	5
93	Implications of genetic heterogeneity in hepatocellular cancer. Advances in Cancer Research, 2022, , 103-135.	1.9	5
94	Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World Journal of Hepatology, 2021, 13, 1107-1121.	0.8	4
95	Treacherous apoptosisâ€"Cancer cells sacrifice themselves at the altar of heterogeneity. Hepatology, 2022, 76, 549-550.	3.6	4
96	Influence of transjugular intrahepatic portosystemic shunt in patients awaiting orthotopic liver transplant on post-transplant outcome. Gastrointestinal Intervention, 2012, 1, 69-73.	0.1	3
97	Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Nonâ€"Hepatocellular Carcinoma Factors. Liver Transplantation, 2021, 27, 684-698.	1.3	3
98	Chemoembolization Combined with RFA for HCC:Survival Benefits and Tumor Treatment Response. Journal of Cancer Therapy, 2013, 04, 493-499.	0.1	3
99	890 ALT ABNORMALITIES IN ADULTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY. Journal of Hepatology, 2011, 54, S354.	1.8	2
100	Response to Houlihan et al.. American Journal of Gastroenterology, 2013, 108, 1807.	0.2	2
101	Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat. Clinical Liver Disease, 2021, 17, 169-173.	1.0	2
102	Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses, 2021, 13, 1318.	1.5	2
103	537 A SUSTAINED VIRAL RESPONSE DRAMATICALLY IMPROVES SURVIVAL IN PATIENTS WITH HEPATITIS C INFECTION AFTER LIVER TRANSPLANT. Journal of Hepatology, 2011, 54, S219-S220.	1.8	1
104	Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation. Digestive Diseases and Sciences, 2013, 58, 1403-1409.	1.1	1
105	Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Postâ€transplant Clinical Outcome. Clinical Transplantation, 2020, 34, e14128.	0.8	1
106	Incidentally Discovered HCC (iHCC) in Explant Liver-Histopathologic Features and Clinical Outcome. Journal of Cancer Therapy, 2013, 04, 394-398.	0.1	1
107	S1920 Influence of Patient Age on Short Term and Long Term Survival After Tips. Gastroenterology, 2010, 138, S-817-S-817.	0.6	0
108	Abstract No. 244: Survival outcomes of doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) for advanced hepatocellular carcinoma (HCC). Journal of Vascular and Interventional Radiology, 2011, 22, S104.	0.2	0

#	Article	IF	Citations
109	Treatment Outcomes and Prognostic Factors for Intrahepatic Cholangiocarcinoma Single Center Experience. Gastroenterology, 2011, 140, S-920.	0.6	0
110	Abstract No. 323: Transjugular intrahepatic portosystemic shunt (TIPS): Time trends in etiology of cirrhosis, indications, and survival. Journal of Vascular and Interventional Radiology, 2011, 22, S134.	0.2	0
111	Mo1891 Rate and Predictors of Progression and Mortality in a Large Population Based Cohort of Be. Gastroenterology, 2013, 144, S-685.	0.6	0
112	Tu1039 Is NASH Related HCC Different From HCC Related to Other Causes. Gastroenterology, 2013, 144, S-1038.	0.6	0
113	Mo1847 Analysis of Paired Biopsies to Assess Progression of Fibrosis in Patients Treated for Post-Transplant Hepatitis C Recurrence. Gastroenterology, 2013, 144, S-1028.	0.6	0
114	Liver Transplantation for Hepatocellular Carcinoma. Current Transplantation Reports, 2014, 1, 215-223.	0.9	0
115	770 Sulfatase2 (SULF2) Promotes Angiogenesis in Hepatocellular Carcinoma Partly Through the TGFÎ²1/Periostin Signaling Pathway. Gastroenterology, 2014, 146, S-927-S-928.	0.6	0
116	639 Female Gender Associated With Less Aggressive Tumor Phenotype and Better Survival in HCC. Gastroenterology, 2014, 146, S-918.	0.6	0
117	P1001 CLINICAL OUTCOMES AFTER RESECTION IN PATIENTS WITH NASH-RELATED HCC. Journal of Hepatology, 2014, 60, S408.	1.8	0
118	585 Comparative Efficacy of Transarterial Radioembolization (TARE) Versus Chemotherapy or Best Supportive Care for Unresectable Intrahepatic Cholangiocarcinoma (iCCA). Gastroenterology, 2015, 148, S-986-S-987.	0.6	0
119	Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver International, 2015, 35, 2625-2625.	1.9	0
120	Sa1858 Undiagnosed Nonalcoholic Steatohepatitis (NASH) Is Responsible for a Significant Proportion of Cryptogenic Hepatocellular Carcinoma (HCC). Gastroenterology, 2015, 148, S-1026.	0.6	0
121	Sa1716 Next Generation Sequencing and Pathway Analysis Reveals Frequent Activation of the PI3-K/Akt Pathway in Gallbladder Cancer: Potential for Targeted Therapy. Gastroenterology, 2015, 148, S-1019.	0.6	0
122	Sa1362 Identification of Novel Fusions in Gallbladder Cancer by Next Generation Sequencing RNA Analysis - Potential for Targeted Therapy. Gastroenterology, 2016, 150, S295-S296.	0.6	0
123	Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.. Journal of Clinical Oncology, 2010, 28, e14559-e14559.	0.8	0
124	Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocelluar carcinoma with portal vein thrombosis.. Journal of Clinical Oncology, 2010, 28, e14638-e14638.	0.8	0
125	Emerging Therapies for Hepatocellular Carcinoma. , 2012, , 263-290.		0
126	Internet Search Patterns for Gastroenterological Symptoms and the Relationship to Physician Visits. American Journal of Gastroenterology, 2013, 108, S477.	0.2	0

#	Article	IF	Citations
127	Comparing Internet Search Patterns for Gastroenterological Diagnoses to Physician Visit Data. American Journal of Gastroenterology, 2013, 108, S477.	0.2	0
128	Abstract 2943: MYC functions as a master switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. , 2017, , .		0
129	MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling. Blood, 2019, 134, 730-730.	0.6	0